Neurodegenerative Disease Industry Overview
|Study Period:||2018 - 2028|
|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
*Disclaimer: Major Players sorted in no particular order
Need a report that reflects how COVID-19 has impacted this market and its growth?
Neurodegenerative Disease Market Analysis
The neurodegenerative disease market was estimated to be USD 45,441.30 million in the base year and is expected to register a CAGR of 6.93% during the forecast period.
COVID-19's impact on the market was significant as it affected workflows of clinical trials, research, development activities, and pipeline products for neurodegenerative diseases, leading to relatively slow growth despite a robust late-stage product pipeline. The delay in product approvals due to the pandemic significantly impacted the market's development. For instance, in January 2021, Biogen and Eisai Co. Ltd reported the United States Food and Drug Administration (FDA) extended the review period by three months for the Biologics License Application for aducanumab, an investigational treatment for Alzheimer's disease. Biogen submitted the aducanumab biologics license application to the FDA in July 2020. The application was accepted in August 2020 and granted priority review. Thus, the market witnessed a short-term growth decline during the pandemic due to the above factors. However, in the later phase, research and development resumed, which positively impacted the market studied.
The major market growth factors include the rising prevalence of neurological disorders, increasing awareness among the global population, and a strong product pipeline for neurodegenerative disease treatment. With the increasing global population and an average lifespan, the prevalence of neurological disorders is on the rise. The National Institute of Environmental Health Sciences data updated in June 2022 stated an estimated 6.2 million people might have Alzheimer's disease in the United States, and nearly a million Americans are living with Parkinson's disease. Additionally, as per the Lancet Journal article published in October 2020, the total number of disability-adjusted life-years (DALYs) attributable to neurological disorders was 21 million in the European Union and 41.1 million in the WHO- European region. Such a burden of neurological disorders is expected to increase the demand for treatments and effective treatment methods, thereby contributing to the growth of the neurodegenerative disease market.
Furthermore, according to Clinicaltrails.gov, in April 2022, a study conducted by Peking Union Medical College Hospital in Beijing, China, was in phase-I and aimed to investigate the radiation dosimetry, plasma pharmacokinetics, biodistribution, safety, and diagnostic performance of (S)-[18F]FBFP in healthy volunteers and patients with central nervous system diseases. Such studies show a trend in developing treatments for neurodegenerative diseases, thereby driving the market's growth.
Thus, the factors above are expected to aid in the growth of the market studied over the forecast period. However, stringent regulatory guidelines and patent expiry of neurodegenerative disease treatment products are the major factors that are anticipated to hinder the market's growth.
Neurodegenerative Disease Industry Segments
As per the scope of the report, neurodegenerative disease is a broad term used to denote a range of conditions that primarily affect the neurons in the brain. Neurodegenerative diseases are incurable, and neuron degradation leads to neurons' gradual death. The market is segmented by indication type (Parkinson's disease, Alzheimer's Disease, multiple sclerosis, Huntington's disease, and other indication types), drug type (N-methyl-D-aspartate receptor antagonists, cholinesterase inhibitors, dopamine agonists, immunomodulatory drugs, and other drug types), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (USD million) for the above segments.
|By Indication Type|
|Other Indication Types|
|By Drug Type|
|N-methyl-D-aspartate Receptor Antagonists|
|Other Drug Types|
Neurodegenerative Disease Market Trends
This section covers the major market trends shaping the Neurodegenerative Disease Market according to our research experts:
Alzheimer's Disease is Expected to Witness Significant Growth Over the Forecast Period
Alzheimer's disease is expected to hold a significant market share over the forecast period. It is a progressive disorder that causes brain cells to waste away (degenerate) and die. It is the most common cause of dementia, a continuous decline in thinking, behavioral, and social skills that disrupts a person's ability to function independently. The prevalence and mortality due to the disease are increasing globally. Thus, the demand for treatments and therapies for the disease is increasing, thereby driving the market's growth.
The increasing prevalence of Alzheimer's disease is seen globally. For instance, according to the 2021 Alzheimer's Disease Facts and Figures report released by the Alzheimer's Association, it was estimated that in the United States, around 6.2 million people aged 65 and older were living with Alzheimer's dementia in 2021. In addition, as per the source mentioned above, 1 in 9 people aged 65 and older has Alzheimer's dementia, and about two-thirds of Americans with Alzheimer's are women. The high incidence of Alzheimer's disease is expected to positively impact the market's growth.
Additionally, the growing research and development activities and new products launched aid the segment's growth. For instance, in January 2021, Eli Lilly and Company revealed the results of a study on Donanemab. This investigational antibody targets a modified form of beta-amyloid called N3pG, which showed a significant slowing decline in a composite measure of cognition and daily function in patients with early symptomatic Alzheimer's disease compared to placebo in results from its Phase 2 TRAILBLAZER-ALZ study. On June 10th, 2021, the US Food and Drug Administration (FDA) granted accelerated approval for Biogen's and Eisai's Aduhelm (aducanumab) for treating Alzheimer's disease. Such developments in the studied segment are expected to drive its growth. Thus, owing to the factors above, the Alzheimer's disease segment is expected to witness a significant increase in the coming years.
To understand key trends, Download Sample Report
North America is Expected to Dominate the Market Over the Forecast Period
North America is expected to be the most significant neurodegenerative disease market. Factors affecting the growth of the market studied are the increasing number of neurological disorders, and research and development by private and government organizations focused on developing treatments for such diseases.
As per the Alzheimer's Association 2022 Alzheimer's Disease Facts and Figures, an estimated 6.5 million Americans aged 65 and older were living with Alzheimer's dementia in 2022 in the United States. By 2050, the number of people aged 65 and older with Alzheimer's dementia is projected to increase to 12.7 million. This high burden of Alzheimer's disease surges the demand for novel therapeutics in its treatment, thereby leading to the growth of the market studied in the country.
Moreover, North America is expected to hold a significant market share due to the presence of many drug manufacturers and the advancing paradigm of care for neurodegenerative disease patients, supporting the growth. For instance, in June 2022, the Food and Drug Administration launched an action plan for rare neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS). This action plan is the five-year strategy implemented to improve and extend the lives of people living with rare neurodegenerative diseases across the country. The project's primary focus is on advancing the development of safe and effective medical products and providing complete access to novel treatments for all. Additionally, in January 2022, Alterity Therapeutics, a company focused on the development of disease-modifying therapies for neurodegenerative diseases, announced a new US patent for compounds for neurodegenerative diseases, including Parkinson's and Alzheimer's. Therefore, with numerous drug development and approval-related activities, the market studied is believed to witness significant growth over the forecast period. Hence, owing to the above factors, the market is anticipated to grow in the North American region over the forecast period.
To understand geography trends, Download Sample Report
Neurodegenerative Disease Market Competitor Analysis
The market studied is moderately competitive due to a few major market players. The major players are involved in strategic alliances such as mergers and acquisitions, partnerships and collaborations, investments in research and development activities, and new product launches to withstand the global competitive rivalry. Some major market players are AbbVie Inc., Amneal Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Pfizer Inc., Teva Pharmaceuticals, Novartis AG, and UCB SA.
Neurodegenerative Disease Market Top Players
Boehringer Ingelheim International GmbH
Merck & Co Inc.
*Disclaimer: Major Players sorted in no particular order
Neurodegenerative Disease Market Recent Developments
In October 2022, Cyclo Therapeutics launched a Phase 2b study for its investigational drug Trappsol cyclo, which targets the reduction of amyloid beta and tau in treating early Alzheimer's disease.
In August 2022, Amneal Pharmaceuticals submitted a New Drug Application (NDA) to the United States Food and Drug Administration for IPX203, a novel, oral formulation of carbidopa/levodopa extended-release capsules for the treatment of Parkinson's disease.
Neurodegenerative Disease Market Report - Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Neurological Disorders
4.2.2 Increasing Public Awareness
4.2.3 Strong Product Pipeline for Neurodegenerative Disease Treatment
4.3 Market Restraints
4.3.1 Patent Expiry of Neurodegenerative Disease Treatment Products
4.3.2 Stringent Regulatory Guidelines
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Indication Type
5.1.1 Parkinson's Disease
5.1.2 Alzheimer's Disease
5.1.3 Multiple Sclerosis
5.1.4 Huntington Disease
5.1.5 Other Indication Types
5.2 By Drug Type
5.2.1 N-methyl-D-aspartate Receptor Antagonists
5.2.2 Cholinesterase Inhibitors
5.2.3 Dopamine Agonists
5.2.4 Immunomodulatory Drugs
5.2.5 Other Drug Types
5.3 By Geography
5.3.1 North America
18.104.22.168 United States
22.214.171.124 United Kingdom
126.96.36.199 Rest of Europe
188.8.131.52 South Korea
184.108.40.206 Rest of Asia-Pacific
5.3.4 Middle East and Africa
220.127.116.11 South Africa
18.104.22.168 Rest of Middle East and Africa
5.3.5 South America
22.214.171.124 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 AbbVie Inc.
6.1.2 Amneal Pharmaceuticals Inc.
6.1.3 Boehringer Ingelheim International GmbH
6.1.4 F. Hoffmann-La Roche Ltd
6.1.5 Merck & Co. Inc.
6.1.6 Novartis AG
6.1.7 Pfizer Inc.
6.1.8 Teva Pharmaceutical
6.1.9 UCB SA
6.1.10 Biogen Inc.
6.1.11 Johnson and Johnson
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Neurodegenerative Disease Market Research FAQs
What is the study period of this market?
The Neurodegenerative Disease Market is studied from 2018 - 2028.
What is the growth rate of Neurodegenerative Disease Market?
The Neurodegenerative Disease Market is growing at a CAGR of 6.93% over the next 5 years.
What is Neurodegenerative Disease Market size in 2018?
The Neurodegenerative Disease Market is valued at 45441 Million USD in 2018.
What is Neurodegenerative Disease Market size in 2028?
The Neurodegenerative Disease Market is valued at 67525 Million USD in 2028.
Which region has highest growth rate in Neurodegenerative Disease Market?
Asia Pacific is growing at the highest CAGR over 2018 - 2028.
Which region has largest share in Neurodegenerative Disease Market?
North America holds highest share in 2021.
Who are the key players in Neurodegenerative Disease Market?
Boehringer Ingelheim International GmbH, UCB SA, Novartis AG, Teva Pharmaceutical, Merck & Co Inc. are the major companies operating in Neurodegenerative Disease Market.
Neurodegenerative Disease Industry Reports
In-depth industry statistics and market share insights of the Neurodegenerative Disease sector for 2020, 2021, and 2022. The Neurodegenerative Disease research report provides a comprehensive outlook of the market size and an industry growth forecast for 2023 to 2028. Available to download is a free sample file of the Neurodegenerative Disease report PDF.